Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846581 | 0.90 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4950152 | 0.89 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4280246 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL123664 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21275617 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23710653 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1585708 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL566228 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16629728 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800228 | 0.88 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
| CN-119569869-A | SLC15A4 activated antibody and application thereof | 北京理工大学 | 2025-03-07 | — | — | CN | disclosed |
| US-10456463-B2 | Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules | Zoetis Belgium S.A (BE) | 2019-10-29 | — | — | US | disclosed |
| EP-2575878-B1 | VACCINES COMPRISING CHOLESTEROL AND CPG AS SOLE ADJUVANT-CARRIER MOLECULES | ZOETIS BELGIUM S A (BE) | 2018-06-13 | — | — | EP | disclosed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-2575878-A1 | VACCINES COMPRISING CHOLESTEROL AND CPG AS SOLE ADJUVANT - CARRIER MOLECULES | Pfizer Animal Health S.A. (BE) | 2013-04-10 | — | — | EP | disclosed |
| US-20130084306-A1 | VACCINES COMPRISING CHOLESTEROL AND CPG AS SOLE ADJUVANT-CARRIER MOLECULES | COLEY PHARMACEUTICAL GROUP INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-8252768-B2 | Designer therapy of pancreatic tumors | UNIVERSITY OF MIAMI (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2011148356-A1 | VACCINES COMPRISING CHOLESTEROL AND CPG AS SOLE ADJUVANT - CARRIER MOLECULES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20090325897-A1 | DESIGNER THERAPY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2008085611-A2 | DESIGNER THERAPHY OF PANCREATIC TUMORS | UNIVERSITY OF MIAMI (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20030219805-A1 | Detection of alternative and aberrant mRNA splicing | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE | 2003-11-27 | — | — | US | disclosed |
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | SLC28A1 152/4885SLC28A2 162/4885SLC29A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.